Literature DB >> 18940553

Acute combined central and peripheral nervous system demyelination in children.

Tanja Adamovic1, Emilie M Riou, Geneviève Bernard, Michel Vanasse, Jean-Claude Décarie, Chantal Poulin, France Gauvin.   

Abstract

Reports of acute combined central and peripheral nervous system acquired inflammatory demyelination are rare in children. This study aimed to (1) define the clinical features and prognoses of patients with this entity; and (2) compare these patients with children presenting isolated acute central or peripheral nervous system demyelination. A retrospective chart review of 523 children with central or peripheral nervous system demyelination hospitalized between 1993-2006 was undertaken. Among these, 93 fulfilled criteria (clinical features and positive magnetic resonance imaging or electromyography/nerve conduction studies) for either acute central (n = 37; 39.8%) or peripheral (n = 43; 46%) nervous system demyelination, or a combination of the two (n = 13; 14%). Significant differences between groups were evident for age (median, 10 versus 7 versus 11 years, respectively; P = 0.047), admission to pediatric intensive care unit (8% versus 30% versus 58%, respectively; P = 0.001), length of hospital stay (median, 8 versus 9 versus 29 days, respectively; P < 0.001), treatment with steroids (52% versus 7% versus 75%, respectively; P < 0.001) and immunoglobulins (11% versus 81% versus 75%, respectively; P < 0.001), and poor evolution (3% versus 12% versus 54%, respectively; P = 0.002). This entity in children is not rare, and has a poorer outcome than isolated central or peripheral nervous system demyelination. Assessment is needed for a better understanding of risk factors, etiologies, management, and prognosis.

Entities:  

Mesh:

Year:  2008        PMID: 18940553     DOI: 10.1016/j.pediatrneurol.2008.07.022

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  3 in total

1.  Efficacy of rituximab as third-line therapy in combined central and peripheral demyelination.

Authors:  Salvatore Savasta; Thomas Foiadelli; Elisa Vegezzi; Andrea Cortese; Alessandro Lozza; Anna Pichiecchio; Diego Franciotta; Enrico Marchioni
Journal:  Neurol Clin Pract       Date:  2017-12

2.  Clinical and pharmacological aspects of inflammatory demyelinating diseases in childhood: an update.

Authors:  Alberto Spalice; Pasquale Parisi; Laura Papetti; Francesco Nicita; Fabiana Ursitti; Francesca Del Balzo; Enrico Properzi; Alberto Verrotti; Martino Ruggieri; Paola Iannetti
Journal:  Curr Neuropharmacol       Date:  2010-06       Impact factor: 7.363

Review 3.  Altered mental status in "Guillain-Barré syndrome" -a noteworthy clinical clue.

Authors:  Eoin Mulroy; Neil E Anderson
Journal:  Ann Clin Transl Neurol       Date:  2020-11-02       Impact factor: 5.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.